NI
GBT

Numeric Investors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Numeric Investors’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-54,800
Closed -$1.5M – 1225
2017
Q2 		$1.5M Buy
+54,800
New +$1.63M 0.01% 581

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Numeric Investors's GBT Position: Q3 2017 in Review

Numeric Investors sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2017, closing a stake of 54,800 shares — an estimated $1.5M sold.

Numeric Investors first reported a position in GBT in Q2 2017 and held it in 1 quarter. The position peaked at $1.5M in Q2 2017. 136 funds tracked by Wall St. Rank hold GBT as of Q3 2017.

  • Numeric Investors reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Numeric Investors sold 54,800 Global Blood Therapeutics, Inc. shares in Q3 2017, an estimated $1.5M.
  • Numeric Investors first reported a position in Global Blood Therapeutics, Inc. in Q2 2017 and held it in 1 quarter.
  • Numeric Investors's Global Blood Therapeutics, Inc. position peaked at $1.5M in Q2 2017.
  • 136 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2017.

Based on Numeric Investors's 13F filing for Q3 2017, filed 14 Nov 2017.